Australia - angielski - Department of Health (Therapeutic Goods Administration)

syntara limited - mannitol, quantity: 40 mg - inhalation, powder for - excipient ingredients: gelatin - bronchitol is indicated for the treatment of cystic fibrosis (cf) in adults aged 18 years and above as an add-on therapy. identification of bronchial hyperresponsiveness to inhaled mannitol.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

syntara limited - mannitol, quantity: 40 mg - inhalation, powder for - excipient ingredients: gelatin - bronchitol is a sugar alcohol indicated as add-on maintenance therapy to improve pulmonary function in adult patients 18 years and older with cystic fibrosis. use bronchitol only for adults who have passed the bronchitol tolerance test

Australia - angielski - Department of Health (Therapeutic Goods Administration)

syntara limited - mannitol, quantity: 40 mg - inhalation, powder for - excipient ingredients: gelatin - assessment of bronchial hyperresponsiveness in patients ? 6 years of age or older who do not have clinically apparent asthma.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

syntara limited - mannitol, quantity: 40 mg/g - inhalation, powder for - excipient ingredients: gelatin - bronchitol is indicated for the treatment of cystic fibrosis (cf) in both paediatric and adult populations six years and above as either an add-on therapy to dornase alfa or in patients intolerant to, or inadequately responsive to dornase alfa.

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

physicians total care, inc. - omeprazole (unii: kg60484qx9) (omeprazole - unii:kg60484qx9), sodium bicarbonate (unii: 8mdf5v39qo) (bicarbonate ion - unii:hn1zra3q20) - omeprazole 40 mg - zegerid (omeprazole/sodium bicarbonate) is indicated for short-term treatment of active duodenal ulcer. most patients heal within four weeks. some patients may require an additional four weeks of therapy. [see clinical studies (14.1)] zegerid is indicated for short-term treatment (4-8 weeks) of active benign gastric ulcer. [see clinical studies (14.2)] symptomatic gerd zegerid is indicated for the treatment of heartburn and other symptoms associated with gerd. [see clinical studies (14.3)] erosive esophagitis zegerid is indicated for the short-term treatment (4-8 weeks) of erosive esophagitis which has been diagnosed by endoscopy. the efficacy of zegerid used for longer than 8 weeks in these patients has not been established. if a patient does not respond to 8 weeks of treatment, it may be helpful to give up to an additional 4 weeks of treatment. if there is recurrence of erosive esophagitis or gerd symptoms (e.g., heartburn), additional 4-8 week courses of zegerid may be considered. [see clinical studies (1

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

prasco laboratories - omeprazole (unii: kg60484qx9) (omeprazole - unii:kg60484qx9), sodium bicarbonate (unii: 8mdf5v39qo) (bicarbonate ion - unii:hn1zra3q20) - omeprazole 20 mg - omeprazole/sodium bicarbonate is indicated for short-term treatment of active duodenal ulcer. most patients heal within four weeks. some patients may require an additional four weeks of therapy. [see clinical studies (14.1)] omeprazole/sodium bicarbonate is indicated for short-term treatment (4-8 weeks) of active benign gastric ulcer. [see clinical studies (14.2)] symptomatic gerd omeprazole/sodium bicarbonate is indicated for the treatment of heartburn and other symptoms associated with gerd for up to 4 weeks. [see clinical studies (14.3)] erosive esophagitis omeprazole/sodium bicarbonate is indicated for the short-term treatment (4-8 weeks) of erosive esophagitis which has been diagnosed by endoscopy. the efficacy of omeprazole/sodium bicarbonate used for longer than 8 weeks in these patients has not been established. if a patient does not respond to 8 weeks of treatment, it may be helpful to give up to an additional 4 weeks of treatment. if there is recurrence of erosive esophagitis or gerd symptoms (e.g.,

Malta - angielski - Medicines Authority

dompe farmaceutici spa via san martino 12, 20122, milan, italy - ketoprofen lysine - suppository - ketoprofen lysine 160 mg - antiinflammatory and antirheumatic products

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

oceanside pharmaceuticals - omeprazole (unii: kg60484qx9) (omeprazole - unii:kg60484qx9) - omeprazole 20 mg

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

oceanside pharmaceuticals - omeprazole (unii: kg60484qx9) (omeprazole - unii:kg60484qx9), sodium bicarbonate (unii: 8mdf5v39qo) (bicarbonate ion - unii:hn1zra3q20) - omeprazole 20 mg - omeprazole and sodium bicarbonate for oral suspension and omeprazole and sodium bicarbonate capsules are indicated in adults for the : - short-term treatment of active duodenal ulcer. most patients heal within four weeks. some patients may require an additional four weeks of therapy. - short-term treatment (4 to 8 weeks) of active benign gastric ulcer. - treatment of heartburn and other symptoms associated with gerd for up to 4 weeks. - short-term treatment (4 to 8 weeks) of ee due to acid-mediated gerd which has been diagnosed by endoscopy in adults. - the efficacy of omeprazole and sodium bicarbonate used for longer than 8 weeks in patients with ee has not been established. if a patient does not respond to 8 weeks of treatment, an additional 4 weeks of treatment may be given. if there is recurrence of ee or gerd symptoms (e.g., heartburn), additional 4 to 8-week courses of omeprazole and sodium bicarbonate may be considered. - maintenance of healing of ee due to acid-mediated gerd. controlled studies do not

Kanada - angielski - Health Canada

emd serono, a division of emd inc., canada - cetrorelix (cetrorelix acetate) - powder for solution - 0.25mg - cetrorelix (cetrorelix acetate) 0.25mg - gonadotropin-releasing hormone antagonists